News
-
-
-
PRESS RELEASE
Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports financial results for the first half of 2025, strategic update, and key achievements in sarcopenia and obesity. Plans for Phase 2 and Phase 3 studies outlined with focus on sustaining growth and value creation -
-
REGULATED PRESS RELEASE
BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
BIOPHYTIS and a Consortium of Investors partner to finance and launch Phase 3 Trial in Sarcopenia, creating a joint venture in Hong Kong with US$20 million investment for clinical operations starting early 2026 -
-
-
-
REGULATED PRESS RELEASE
Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII -
